SINOPHARM (01099) has announced its financial results for the first nine months of 2025, reporting an operating revenue of approximately 431.479 billion yuan, a year-on-year decrease of 2.47%. The net profit attributable to the parent company is about 5.307 billion yuan, reflecting a year-on-year growth of 0.53%. The basic earnings per share stand at 1.7 yuan.